Header Logo

Connection

Sonal Singh to Cardiovascular Diseases

This is a "connection" page, showing publications Sonal Singh has written about Cardiovascular Diseases.
Connection Strength

2.877
  1. Erskine N, Tran H, Levin L, Ulbricht C, Fingeroth J, Kiefe C, Goldberg RJ, Singh S. A systematic review and meta-analysis on herpes zoster and the risk of cardiac and cerebrovascular events. PLoS One. 2017; 12(7):e0181565.
    View in: PubMed
    Score: 0.381
  2. Alexander GC, Iyer G, Lucas E, Lin D, Singh S. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. Am J Med. 2017 Mar; 130(3):293-305.
    View in: PubMed
    Score: 0.361
  3. Hayman KG, Sharma D, Wardlow RD, Singh S. Burden of cardiovascular morbidity and mortality following humanitarian emergencies: a systematic literature review. Prehosp Disaster Med. 2015 Feb; 30(1):80-8.
    View in: PubMed
    Score: 0.318
  4. Loke YK, Ho R, Smith M, Wong O, Sandhu M, Sage W, Singh S. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride. J Clin Pharm Ther. 2013 Oct; 38(5):405-15.
    View in: PubMed
    Score: 0.287
  5. Singh S, Loke YK. Flaws in analysis lead to misleading conclusions about varenicline's safety in smoking cessation. BMJ. 2012 Jun 12; 344:e3873; author reply e4033.
    View in: PubMed
    Score: 0.267
  6. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011 Sep 06; 183(12):1359-66.
    View in: PubMed
    Score: 0.250
  7. Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J. 2010 May; 35(5):1003-21.
    View in: PubMed
    Score: 0.224
  8. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 Sep 24; 300(12):1439-50.
    View in: PubMed
    Score: 0.207
  9. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007 Sep 12; 298(10):1189-95.
    View in: PubMed
    Score: 0.192
  10. Onasanya O, Iyer G, Lucas E, Lin D, Singh S, Alexander GC. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. Lancet Diabetes Endocrinol. 2016 11; 4(11):943-956.
    View in: PubMed
    Score: 0.090
  11. Puhan MA, Yu T, Stegeman I, Varadhan R, Singh S, Boyd CM. Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer. BMC Med. 2015 Oct 01; 13:250.
    View in: PubMed
    Score: 0.084
  12. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O, Briel M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011 Feb; 104(2):109-24.
    View in: PubMed
    Score: 0.059
  13. Singh S, Furberg CD, Loke YK. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2009 Jan 08; 360(2):186; author reply 187.
    View in: PubMed
    Score: 0.053
  14. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009; 32(3):219-28.
    View in: PubMed
    Score: 0.053
  15. Singh S, Loke YK. The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf. 2008 Sep; 7(5):579-85.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.